Additionally, the intra-peritoneal administration of IDO (indoleamine-pyrrole 2,3-dioxygenase) inhibitor led to a synergistic effect, resulting in a powerful and persistent anti-tumor response [48]. This evidence concerns the gene IDO1 and neoplasm.